MPP-Home

en / fr

Using our successes to build a broader future – an end of year message from Charles Gore

Charles Gore reflects on his first months as MPP Executive Director and looks ahead to a broader role for the MPP.

The Medicines Patent Pool signs licence with AbbVie to expand access to key hepatitis C treatment, glecaprevir/pibrentasvir

The licence will enable quality-assured manufacturers to develop and sell generic medicines containing G/P in low- and middle-income countries at affordable prices, enabling access to and treatment scale-up with the most effective pan-genotypic regimens.

The Medicines Patent Pool Presents New Five-Year Strategy For Improving Access To Priority Treatments In Developing Countries

Strategy and Related Feasibility Study Call for the Expansion of the MPP’s Mandate to Patented Medicines on the World Health Organization’s Model List of Essential Medicines

Exploring The Expansion Of The Medicines Patent Pool’s Mandate To Patented Essential Medicines

A Feasibility Study Of The Public Health Needs And Potential Impact

Who We Are

The Medicines Patent Pool (MPP) is a United Nations-backed public health organisation working to increase access to, and facilitate the development of, life-saving medicines for low- and middle-income countries.

Vision & Mission

Our Model

Strategy

Governance & Team

Funding

Who We Work With

MedsPaL

The Medicines Patents & Licences Database

The MPP’s patents and licences database, MedsPaL, is a resource that provides information on the intellectual property status of selected HIV, hepatitis C, tuberculosis and other patented essential medicines in low- and middle-income countries.

Additional information and disclaimers

Transparency

All MPP licences are publicly available in their entirety on our website. This is unprecedented in the pharmaceutical field.

Licence Overview

Update on Progress of Sublicensees

Projections

Projections Tool

MPP in Numbers

Hover over the numbers to find out more

9 patent holders with MPP signed agreements

19 million patient-years through MPP’s generic partners from January 2012 to June 2018

24 generic manufacturers and product developers sublicensed from the MPP

18 products licensed to the MPP

150+

150+ ongoing pharmaceutical development projects

87% to 91%

87% to 91% of people living with HIV in developing countries covered by the MPP adult licences

92 to 131

92 to 131 countries covered by MPP adults licences

631

631 million dollars saved, from January 2012 to June 2018

Latest News

05 March 2019

The Medicines Patent Pool Governance Board announces representation from the World Health Organization

Geneva, 5 March 2019 - The Medicines Patent Pool (MPP) Governance Board has announced the appointment of Dr Mariângela Batista Galvão Simão, Assistant Director-General for Drug Access, Vaccines and Pharmaceuticals at the World Health Organization (WHO), as a non-voting participant. This is a unique appointment and will play a key role in supporting the development of the MPP’s mandate expansion into patented essential medicines on the WHO’s Essential Medicines List (EML) and those with strong potential for future inclusion.“all disease areas, and for all patented essential medicines on the WHO EML to be licensed into the Pool.” The MPP launched a new five-year strategy in May 2018, following a feasibility study exploring an increased remit. “This appointment not only reflects the close working relationship between the MPP and the WHO, but is also crucial for enabling the MPP to align with WHO’s global health priorities, as we look to focus on our mandate expansion and where we can have most impact in ad...

29 January 2019

MPP Statement at the 144th session of the WHO Executive Board on Cancer Medicines

MPP statement at the 144th session of the WHO Executive Board on 29 January 2019, item 5.7.2: Speaker: Esteban Burrone The Medicines Patent Pool (MPP) welcomes the opportunity to comment on the report. We note that the document mentions voluntary license agreements as one option to enhance affordability and accessibility. Voluntary licences have played a strong role in facilitating access in other areas such as HIV and hepatitis C. Licences between the MPP and patent holders have enabled early entry of generic manufacturers and price competition in low- and middle-income countries (LMICs). As a result, health systems were able to procure effective new treatments at more affordable prices. Originators received a royalty. And millions of people gained access to treatments. Last year, following strong support from WHO Member States, the MPP expanded its mandate to work on other patented essential medicines, which could include priority cancer medicines. We are currently working with the WHO and ot...

29 January 2019

MPP Statement at 144th session of the WHO Executive Board on Access to Medicines

MPP statement at the 144th session of the WHO Executive Board on 29 January 2019, item 5.7.1: Speaker: Elena Villanueva The Medicines Patent Pool (MPP) welcomes the WHO Roadmap and the inclusion of public health-oriented licensing agreements as a way to foster access to health products. The MPP, established by Unitaid, has become the main driver of public health-oriented licensing agreements for access to medicines in low- and middle-income countries (LMICs). It has already enabled over 100 countries to get faster access to new HIV and hepatitis C treatments at affordable prices and in suitable formulations. We note the Roadmap proposes as a deliverable support for the expansion of the MPP to other patented essential medicines through identification of potential products for licensing. As part of this process, earlier this week, within the framework of the WHO Technical Consultation on the Essential Medicines Lists (EMLs), the MPP consulted with a number of Member States on which essential medici...

Videos

Unable to load video, please allow cookie

Endorsements

“I am honoured to be invited to represent the WHO on the MPP’s Governance Board. Access to essential medicines is fundamental to the ability of everyone to achieve the highest attainable standard of health and core to the Sustainable...”

Unable to load twitter timeline, please allow cookie